Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study

References

• Steinberg D, Witztum JL. Lipoprotein and atherogenesis: current concepts. JAMA 1990;264:3047–521Steinberg D, Witztum JL. Lipoprotein and atherogenesis: current concepts. JAMA 1990;264:3047–52
   PubMed Web of Science ®Google Scholar
• Grundy SM. Cholesterol and coronary heart disease. The 21st century. Arch Intern Med 1997;157:1177–842Grundy SM. Cholesterol and coronary heart disease. The 21st century. Arch Intern Med 1997;157:1177–84
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301–73Shepherd J, Cobbe SM, Ford I, et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301–7
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–94Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–575The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349–57
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–226Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22
   PubMed Web of Science ®Google Scholar
• Nissen S, Tuczu EM, Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomised controlled trial. JAMA 2004;291:1071–807Nissen S, Tuczu EM, Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomised controlled trial. JAMA 2004;291:1071–80
   PubMed Web of Science ®Google Scholar
• Evans M, Roberts A, Davies S. et al. Medical lipid-regulating therapy. Current evidence, ongoing trials and future developments. Drugs 2004;64:1181–968Evans M, Roberts A, Davies S. et al. Medical lipid-regulating therapy. Current evidence, ongoing trials and future developments. Drugs 2004;64:1181–96
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD. et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–359LaRosa JC, Grundy SM, Waters DD. et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35
   PubMed Web of Science ®Google Scholar
• Ridker PM, Morrow DA, Rose LM. et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein < 2 mg/l: an analysis of the PROVEIT TIMI-22 trial. J Am Coll Cardiol 2005;45:1644–810Ridker PM, Morrow DA, Rose LM. et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol < 70 mg/dl and C-reactive protein < 2 mg/l: an analysis of the PROVEIT TIMI-22 trial. J Am Coll Cardiol 2005;45:1644–8
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Bairey Merz CN, et al., for the Coordinating Committee of the NCEP. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110:227–39.11Grundy SM, Cleeman JI, Bairey Merz CN, et al., for the Coordinating Committee of the NCEP. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110:227–39.
   PubMed Web of Science ®Google Scholar
• O’Keefe JH, Cordain L, Harris WH. et al. Optimal low-density lipoprotein is 50–70 mg/dl. J Am Coll Cardiol 2004;43:2142–612O’Keefe JH, Cordain L, Harris WH. et al. Optimal low-density lipoprotein is 50–70 mg/dl. J Am Coll Cardiol 2004;43:2142–6
   PubMed Web of Science ®Google Scholar
• Bosner MS, Ostlund RE Jr, Osofisan O. et al. Assessment of percent cholesterol absorption in humans with stable isotopes. J Lipid Res 1993;34:1047–5313Bosner MS, Ostlund RE Jr, Osofisan O. et al. Assessment of percent cholesterol absorption in humans with stable isotopes. J Lipid Res 1993;34:1047–53
   PubMed Web of Science ®Google Scholar
• Miettinen TA. Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy. Int J Clin Pract 2001;55: 710–1614Miettinen TA. Cholesterol absorption inhibition: a strategy for cholesterol-lowering therapy. Int J Clin Pract 2001;55: 710–16
   PubMed Web of Science ®Google Scholar
• Turley SD. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin Cardiol 2004;27 (Suppl III):III-16–2115Turley SD. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin Cardiol 2004;27 (Suppl III):III-16–21
   Google Scholar
• Norata GD, Catapano AL. Lipid lowering activity of drugs affecting cholesterol absorption. Nutr Metab Cardiovasc Dis 2004;14:42–5116Norata GD, Catapano AL. Lipid lowering activity of drugs affecting cholesterol absorption. Nutr Metab Cardiovasc Dis 2004;14:42–51
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lutjohann D, Kodal A. et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943–817Sudhop T, Lutjohann D, Kodal A. et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation 2002;106:1943–8
   PubMed Web of Science ®Google Scholar
• Bays HE, Moore PB, Drehobl MA, et al., Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209–30.18Bays HE, Moore PB, Drehobl MA, et al., Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209–30.
   PubMed Web of Science ®Google Scholar
• Ezzet F, Wexler D, Statkevich P. et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol 2001;41:943–919Ezzet F, Wexler D, Statkevich P. et al. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. J Clin Pharmacol 2001;41:943–9
   PubMed Web of Science ®Google Scholar
• Bays H. Ezetimibe. Exp Opin Investig Drugs 2002;11:1587–60420Bays H. Ezetimibe. Exp Opin Investig Drugs 2002;11:1587–604
   PubMed Web of Science ®Google Scholar
• Wang DQH. New concepts of mechanisms of intestinal cholesterol absorption. Ann Hepatol 2003;2:113–2121Wang DQH. New concepts of mechanisms of intestinal cholesterol absorption. Ann Hepatol 2003;2:113–21
   PubMedGoogle Scholar
• Knopp RH, Gitter H, Truitt T. et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24: 729–4122Knopp RH, Gitter H, Truitt T. et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24: 729–41
   PubMed Web of Science ®Google Scholar
• Lipka LJ. Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovasc Drug Rev 2003;21:293–31223Lipka LJ. Ezetimibe: a first-in-class, novel cholesterol absorption inhibitor. Cardiovasc Drug Rev 2003;21:293–312
   PubMed Web of Science ®Google Scholar
• Davidson MH. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther 2003;1:11–2124Davidson MH. Ezetimibe: a novel option for lowering cholesterol. Expert Rev Cardiovasc Ther 2003;1:11–21
   PubMedGoogle Scholar
• Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003;25:2352–8725Jeu L, Cheng JW. Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor. Clin Ther 2003;25:2352–87
   PubMed Web of Science ®Google Scholar
• Jurado J, Seip R, Thompson PD. Effectiveness of ezetimibe in clinical practice. Am J Cardiol 2004;93:641–326Jurado J, Seip R, Thompson PD. Effectiveness of ezetimibe in clinical practice. Am J Cardiol 2004;93:641–3
   PubMed Web of Science ®Google Scholar
• Gagne C, Bays HE, Weiss SR, et al., Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-91.27Gagne C, Bays HE, Weiss SR, et al., Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-91.
   PubMed Web of Science ®Google Scholar
• Gagne C, Gaudet D, Bruckert E, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469–75.28Gagne C, Gaudet D, Bruckert E, Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469–75.
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Meyer I, Veltri EP. et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54:309–1929Kosoglou T, Meyer I, Veltri EP. et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002; 54:309–19
   Google Scholar
• Davidson MH, McGarry T, Bettis R. et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125–3430Davidson MH, McGarry T, Bettis R. et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125–34
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A. et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. Circulation 2003;107:2409–1531Ballantyne CM, Houri J, Notarbartolo A. et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. Circulation 2003;107:2409–15
   PubMed Web of Science ®Google Scholar
• Kerzner B, Corbelli J, Sharp S. et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418–2432Kerzner B, Corbelli J, Sharp S. et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418–24
   PubMed Web of Science ®Google Scholar
• Melani L, Mills R, Hassman D. et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717–2833Melani L, Mills R, Hassman D. et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717–28
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Yang B. et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004;20:1185–9534Kosoglou T, Statkevich P, Yang B. et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004;20:1185–95
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Sapre A, Liu J, et al., for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Mayo Clin Proc 2004;79:620–9.35Goldberg AC, Sapre A, Liu J, et al., for the Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Mayo Clin Proc 2004;79:620–9.
   PubMed Web of Science ®Google Scholar
• Feldman T, Koren M, Insull W Jr et al. Treatment of high risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481–636Feldman T, Koren M, Insull W Jr et al. Treatment of high risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481–6
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Meyer I. et al. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin 2004;20:955–6537Kosoglou T, Statkevich P, Meyer I. et al. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin 2004;20:955–65
   PubMed Web of Science ®Google Scholar
• Stein E, Stender S, Mata P, et al., Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55.38Stein E, Stender S, Mata P, et al., Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447-55.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR. et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487–9439Ballantyne CM, Blazing MA, King TR. et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487–94
   PubMed Web of Science ®Google Scholar
• Davidson MH, Ballantyne CM, Kerzner B, et al., Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746–55.40Davidson MH, Ballantyne CM, Kerzner B, et al., Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int J Clin Pract 2004;58:746–55.
   PubMed Web of Science ®Google Scholar
• Lipka L, Sager P, Strony J, et al., Ezetimibe Study Group. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004;21:1025–32.41Lipka L, Sager P, Strony J, et al., Ezetimibe Study Group. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004;21:1025–32.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE. et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587–9542Pearson TA, Denke MA, McBride PE. et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587–95
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z. et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464–7343Ballantyne CM, Abate N, Yuan Z. et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464–73
   PubMed Web of Science ®Google Scholar
• Farnier M, Volpe M, Massaad R. et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005;102:327–3244Farnier M, Volpe M, Massaad R. et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005;102:327–32
   PubMed Web of Science ®Google Scholar
• Brohet C, Banai S, Alings AM. et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005;21:571–845Brohet C, Banai S, Alings AM. et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005;21:571–8
   PubMed Web of Science ®Google Scholar
• Catapano A, Brady WE, King TR. et al. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005;21:1123–3046Catapano A, Brady WE, King TR. et al. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005;21:1123–30
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Fruchart JC. et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004;20:1197–20747Kosoglou T, Statkevich P, Fruchart JC. et al. Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe. Curr Med Res Opin 2004;20:1197–207
   PubMed Web of Science ®Google Scholar
• Zetia [package insert]. North Wales, Pa: Merck/Schering Plough Pharmaceuticals 2003.48Zetia [package insert]. North Wales, Pa: Merck/Schering Plough Pharmaceuticals 2003.
   Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM. et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23: 2009–2649Mikhailidis DP, Sibbring GC, Ballantyne CM. et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23: 2009–26
   PubMed Web of Science ®Google Scholar
• DeBacker G, Ambrosio GB, Amouyel P, et al. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey programme. Eur Heart J 2001;22:554–72.50DeBacker G, Ambrosio GB, Amouyel P, et al. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II Euro Heart Survey programme. Eur Heart J 2001;22:554–72.
   PubMed Web of Science ®Google Scholar
• Keber I, Fras Z, Gužič Salobir B, et al. Rehabilitation and secondary prevention in patients after myocardial infarction. National Clinical Guideline. Ljubljana: Ministry of Health of the Republic of Slovenia, 2004: pp. 1–77.51Keber I, Fras Z, Gužič Salobir B, et al. Rehabilitation and secondary prevention in patients after myocardial infarction. National Clinical Guideline. Ljubljana: Ministry of Health of the Republic of Slovenia, 2004: pp. 1–77.
   Google Scholar
• Fras Z, Maučec-Zakotnik J. Cardiovascular diseases and great prevalence of risk factors for them in the modern society – Slovene perspective. In: Promoting Health through Physical Activity and Nutrition – International Conference. Radenci, Slovenia, April 18–21;2002. pp. 82–652Fras Z, Maučec-Zakotnik J. Cardiovascular diseases and great prevalence of risk factors for them in the modern society – Slovene perspective. In: Promoting Health through Physical Activity and Nutrition – International Conference. Radenci, Slovenia, April 18–21;2002. pp. 82–6
   Google Scholar
• Phillips LS, Branch WT, Cook CB. et al. Clinical inertia. Ann Intern Med 2001;135:825–3453Phillips LS, Branch WT, Cook CB. et al. Clinical inertia. Ann Intern Med 2001;135:825–34
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF. et al. Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90: 1092–754Dujovne CA, Ettinger MP, McNeer JF. et al. Ezetimibe Study Group. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90: 1092–7
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR. et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183–9255Gazi IF, Daskalopoulou SS, Nair DR. et al. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183–92
   PubMed Web of Science ®Google Scholar
• Dietschy JM. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr 1997;65:1581S–9S56Dietschy JM. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr 1997;65:1581S–9S
   PubMedGoogle Scholar
• Santosa S, Varady KA, AbuMweis S. et al. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci 2007;80:505–1457Santosa S, Varady KA, AbuMweis S. et al. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci 2007;80:505–14
   Google Scholar
• Farnier M, Freeman MW, Macdonell G, et al. the Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. Eur Heart J 2005;26:897–905.58Farnier M, Freeman MW, Macdonell G, et al. the Ezetimibe Study Group. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidemia. Eur Heart J 2005;26:897–905.
   PubMed Web of Science ®Google Scholar
• McKenney JM, Farnier M, Lo KW. et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47:1584–759McKenney JM, Farnier M, Lo KW. et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006; 47:1584–7
   PubMed Web of Science ®Google Scholar
• Simons L, Tonkon M, Masana L. et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004;20:1437–4560Simons L, Tonkon M, Masana L. et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004;20:1437–45
   PubMed Web of Science ®Google Scholar
• Sager PT, Melani L, Lipka L, et al., Ezetimibe Study Group. Effect of coadministration coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414–18.61Sager PT, Melani L, Lipka L, et al., Ezetimibe Study Group. Effect of coadministration coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414–18.
   PubMed Web of Science ®Google Scholar
• Geiss HC, Otto C, Parhofer KG. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism 2006;55:599–60462Geiss HC, Otto C, Parhofer KG. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism 2006;55:599–604
   PubMed Web of Science ®Google Scholar
• Ose L, Reyes R, Johnson-Levonas AO. et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007;29:2419–3263Ose L, Reyes R, Johnson-Levonas AO. et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007;29:2419–32
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I. et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23:1169–7664Kalogirou M, Tsimihodimos V, Gazi I. et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23:1169–76
   PubMed Web of Science ®Google Scholar
• Rawlins MD, Jefferys DB. Study of United Kingdom product licence applications containing new active substances, 1987–9. BMJ 1991;302:223–565Rawlins MD, Jefferys DB. Study of United Kingdom product licence applications containing new active substances, 1987–9. BMJ 1991;302:223–5
   PubMed Web of Science ®Google Scholar